Bristol-Myers Squibb Company

Report azionario NYSE:BMY

Capitalizzazione di mercato: US$123.6b

Bristol-Myers Squibb Crescita futura

Criteri Future verificati 1/6

Si prevede che il fatturato e gli utili di Bristol-Myers Squibb diminuiscano rispettivamente di 6.6% e 2.4% all'anno. Si prevede che l'EPS diminuisca di 1% all'anno. Il rendimento del capitale proprio è previsto a 37.4% tra 3 anni.

Informazioni chiave

-2.4%

Tasso di crescita degli utili

-1.03%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili14.9%
Tasso di crescita dei ricavi-6.6%
Rendimento futuro del capitale proprio37.39%
Copertura analitica

Good

Ultimo aggiornamento16 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Jul 03

Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes

Summary BMY’s growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1’26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow. I reiterate my Buy rating for patient, income-oriented investors, with the recommendation to accumulate at yields above 4.2% for an inflation beating income thesis. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 16

BMY: Late Stage Pipeline Wins And Policy Risks Will Drive Re Rating

Analysts slightly revised their average price target for Bristol-Myers Squibb stock, reflecting updated views on a modestly softer revenue outlook, stable fair value near $75.00, and largely unchanged long term margin and P/E assumptions following recent commentary on Medicare negotiation risk. Analyst Commentary Bristol-Myers Squibb continues to attract mixed but constructive attention from Wall Street, with recent notes focusing on Medicare negotiation risk, price target fine-tuning, and how current valuation lines up with long term earnings power.
Articolo di analisi • Jun 16

Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion

Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, adding new casdatifan arms to the ROSETTA RCC-208 study. See our latest analysis for Bristol-Myers Squibb. The kidney cancer trial expansion comes after a mixed period for Bristol-Myers Squibb, with the share price at $56.24, a year to date share price return of 5.2%, and a 1 year total shareholder return of 21.35%. This suggests...
Aggiornamento narrativa • Jun 02

BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating

Analysts have raised the average Bristol-Myers Squibb price target by a few dollars, citing a series of recent upward revisions into the $60 to $70 range. These revisions reflect ongoing debate around macro risks, healthcare sector positioning, and upcoming Milvexian Phase III data.
Aggiornamento narrativa • May 18

BMY: Pipeline Execution And Macro Shifts Will Shape Future Risk Balance

Analysts now see Bristol-Myers Squibb’s fair value edging down by $0.08 to $62.96, as they factor in slightly weaker revenue growth and profit margin assumptions alongside a higher future P/E, even as recent Street price target moves reflect mixed views on the stock’s pipeline and macro setup. Analyst Commentary Recent Street commentary on Bristol-Myers Squibb highlights a wide range of views on execution risk, pipeline delivery and how those factors may feed into valuation over the next few years.
Aggiornamento narrativa • May 03

BMY: Upcoming Late Stage Readouts Will Drive Potential Re Rating Opportunity

Analysts have made only a modest adjustment to their Bristol-Myers Squibb outlook, with small changes to revenue and profitability assumptions feeding into updated price targets that cluster in a wide range from about $60 to $75. This reflects differing views on the pipeline and upcoming Milvexian data as potential drivers for the story.
Aggiornamento narrativa • Apr 19

BMY: Pipeline Progress And Sector Shifts Will Shape Future Risk Balance

Analysts have raised the implied fair value for Bristol-Myers Squibb to $63.04 from $59.91, reflecting a series of recent price target increases based on slightly less severe revenue contraction expectations, a modest improvement in projected profit margins, and support from pipeline-related research updates across multiple firms. Analyst Commentary Recent research has focused on how Bristol-Myers Squibb balances patent expirations on key products with progress in its pipeline and late stage programs, and how that mix feeds into valuation, execution risk, and potential growth beyond current revenue headwinds.
Aggiornamento narrativa • Apr 04

BMY: 2026 Catalyst Calendar Will Likely Fail To Offset Patent Cliff

Analyst price targets for Bristol-Myers Squibb have moved higher into a broad $60 to $75 range, with analysts pointing to a rich 2026 catalyst calendar, emerging pipeline readouts such as milvexian Phase III data, and relatively lower exposure to AI disruption risks as key supports for the updated views. Analyst Commentary Recent research highlights a mix of optimism and caution around Bristol-Myers Squibb, with the Street focusing on a packed 2026 catalyst calendar, milvexian Phase III data, and a broad set of late stage assets.
Aggiornamento narrativa • Mar 21

BMY: 2026 Late Stage Pipeline Catalysts Will Likely Limit Further Upside

The analyst price target for Bristol Myers Squibb has moved higher, with the fair value estimate shifting from $40.67 to $45.67 as analysts point to a richer pipeline of late stage catalysts, a higher projected profit margin, and sector wide support from the appeal of healthcare during a choppy macro backdrop. Analyst Commentary Recent research coverage on Bristol Myers Squibb has tilted more constructive, with several firms lifting price targets into the US$60 to US$75 range and highlighting a dense calendar of late stage readouts through 2026.
Aggiornamento narrativa • Mar 06

BMY: 2026 Late-Stage Pipeline Readouts Will Shape Re-Rating Potential

Analysts have lifted their Bristol Myers Squibb fair value estimate from $68.00 to $75.00, citing higher Street price targets and an increased focus on pipeline catalysts such as the Phase III milvexian data and a dense slate of 2026 readouts. Analyst Commentary Recent Street research on Bristol Myers Squibb clusters around a more constructive view of the pipeline, especially the 2026 readout slate and the Phase III milvexian program, with several firms revisiting their valuation frameworks in light of these potential catalysts.
Aggiornamento narrativa • Feb 20

BMY: 2026 Pipeline Catalysts And Sector Recovery Will Shape Risk Balance

Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to about $60. This reflects how recent price target increases and generally constructive research commentary around the pipeline are starting to offset concerns about upcoming patent expirations.
Articolo di analisi • Feb 18

We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit

Bristol-Myers Squibb Company ( NYSE:BMY ) announced a healthy earnings result recently, and the market rewarded it with...
Aggiornamento narrativa • Feb 06

BMY: 2026 Pipeline Readouts And Sector Recovery Will Guide Next Repricing

Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to US$58.13 from US$56.26. This reflects updated Street research in which analysts cite a richer mix of potential 2026 pipeline catalysts and a slightly higher assumed future P/E multiple, both of which support recent price target increases across several firms.
Aggiornamento narrativa • Jan 23

BMY: 2026 Pipeline Readouts Will Likely Cap Near Term Upside

Analysts have lifted their blended price target on Bristol Myers Squibb by roughly US$2 to reflect higher estimated fair value and profitability, citing a rich set of 2026 pipeline readouts and what they view as underappreciated upside in several late-stage assets. Analyst Commentary Recent Street research on Bristol Myers Squibb points to a mixed but generally constructive stance, with several firms lifting price targets into the US$53 to US$65 range and highlighting what they see as meaningful 2026 data catalysts across eight late stage assets.
Aggiornamento narrativa • Jan 08

BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating

Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.
Aggiornamento narrativa • Dec 25

BMY: Sector Perform View Will Limit Upside Despite Upcoming Earnings Focus

Analysts have nudged their fair value estimate for Bristol-Myers Squibb higher to about $38.41 from $35.86, reflecting a modestly richer future earnings multiple despite slightly weaker near term revenue growth and margin assumptions, and a new $45 price target under a Sector Perform view. Analyst Commentary Recent Street commentary frames Bristol-Myers Squibb as a lagging, but not broken, story within large cap biopharma.
Aggiornamento narrativa • Dec 11

BMY: Sector Outlook And Policy Shifts Will Shape Next Share Rerating

Analysts have nudged their price target for Bristol-Myers Squibb slightly higher to approximately $54 per share. This reflects a modestly richer future earnings multiple despite expectations for somewhat weaker revenue growth and profit margins, along with a more cautious Sector Perform stance from recent Street research.
Aggiornamento narrativa • Sep 04

Aging Demographics And Genomics Will Drive Healthcare Demand

Analysts maintained a cautious outlook on Bristol-Myers Squibb due to muted Cobenfy prescription trends and pipeline execution concerns, partially offset by optimism for upcoming Alzheimer’s data and future optionality, resulting in the consensus price target remaining steady at $53.00. Analyst Commentary Bearish analysts point to recent moderation in Cobenfy prescriptions for schizophrenia and maintain low growth expectations for this indication in the second half of 2025.

Previsioni di crescita degli utili e dei ricavi

NYSE:BMY - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202840,9758,88514,15014,49021
12/31/202746,39910,24414,64314,91524
12/31/202647,44910,54715,79314,50626
3/31/202648,4827,27511,90813,306N/A
12/31/202548,1947,05412,84514,156N/A
9/30/202548,0346,03915,30216,621N/A
6/30/202547,7045,04914,57815,901N/A
3/31/202547,6365,41913,08614,310N/A
12/31/202448,300-8,94813,94215,190N/A
9/30/202447,435-7,25813,80315,003N/A
6/30/202446,509-6,54112,94514,163N/A
3/31/202445,534-6,14812,50913,724N/A
12/31/202345,0068,02512,65113,860N/A
9/30/202344,9358,28511,46812,914N/A
6/30/202345,1877,96310,49911,850N/A
3/31/202345,8487,31110,86012,224N/A
12/31/202246,1596,32711,94813,066N/A
9/30/202246,7386,67712,94613,817N/A
6/30/202247,1446,61714,50215,396N/A
3/31/202246,9606,25115,34716,195N/A
12/31/202146,3856,99415,23416,207N/A
9/30/202145,468-5,40514,56915,505N/A
6/30/202144,384-5,07911,68712,506N/A
3/31/202142,810-6,21913,21513,939N/A
12/31/202042,518-9,01513,29914,052N/A
9/30/202039,395-4412,15712,878N/A
6/30/202034,862-56312,40913,167N/A
3/31/202031,0069549,93910,757N/A
12/31/201926,1453,439N/A8,210N/A
9/30/201924,1735,655N/A8,458N/A
6/30/201923,8576,203N/A7,181N/A
3/31/201923,2885,144N/A6,155N/A
12/31/201822,5614,920N/A7,066N/A
9/30/201822,0371,432N/A4,628N/A
6/30/201821,600376N/A5,062N/A
3/31/201821,040919N/A5,589N/A
12/31/201720,7761,007N/A5,275N/A
9/30/201720,5704,229N/A5,601N/A
6/30/201720,2384,586N/A5,292N/A
3/31/201719,9654,836N/A4,147N/A
12/31/201619,4274,457N/A3,058N/A
9/30/201618,4713,366N/A2,226N/A
6/30/201617,6182,870N/A1,346N/A
3/31/201616,9101,574N/A978N/A
12/31/201516,5601,565N/A2,105N/A
9/30/201516,5311,775N/A1,793N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di BMY diminuiranno nei prossimi 3 anni ( -2.4% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di BMY diminuiranno nei prossimi 3 anni ( -2.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di BMY diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di BMY diminuiranno nei prossimi 3 anni ( -6.6% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di BMY diminuiranno nei prossimi 3 anni ( -6.6% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di BMY sarà elevato tra 3 anni ( 37.4 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/17 23:57
Prezzo dell'azione a fine giornata2026/07/17 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Bristol-Myers Squibb Company è coperta da 45 analisti. 26 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Emily FieldBarclays
Charles ButlerBarclays